KBY Biotech Indexv0.0.34
Search
← Pipeline|SND-4562

SND-4562

NDA/BLA
By Syndax
Source: Trial-derived·Trials: 1
Modality
Small Molecule
MOA
CAR-T CD19
Target
AuroraA
Pathway
Neuroinflam
MCL
Development Pipeline
Preclinical
~Nov 2012
→ ~Feb 2014
Phase 1
~May 2014
→ ~Aug 2015
Phase 2
~Nov 2015
→ ~Feb 2017
Phase 3
~May 2017
→ ~Aug 2018
NDA/BLA
Nov 2018
NDA/BLACurrent
NCT06224445
1,525 pts·MCL
2018-11→TBD·Recruiting
1,525 total pts1 indication
Approved
CompletedCurrentUpcoming
Trial Timeline
NDA/BLA
Recruit…
Recruiting|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT06224445NDA/BLAMCLRecruiting1525ORR
Competitors (10)
DrugCompanyPhaseTargetMOA
RHH-1546RochePhase 2/3C5CAR-T CD19
DatoglumideAbbVieApprovedCFTRCAR-T CD19
MotarapivirGSKPreclinicalAuroraAIL-23i
BAY-8733BayerPreclinicalAuroraABETi
GIL-2259Gilead SciencesApprovedSMN2CAR-T CD19
BNT-8090BioNTechPhase 2AuroraAPD-L1i
BII-4342BiogenPhase 2/3CGRPCAR-T CD19
ARG-6988ArgenxPreclinicalAuroraACDK2i
TalasotorasibExelixisPreclinicalAPOC3CAR-T CD19
SemamavacamtenIdeaya BioPhase 1/2AuroraABTKi